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Abstract
Introduction: Although serum creatinine is the standard metric tool for the detection of renal
injury, its lack of sensitivity has made the early diagnosis of acute kidney injury (AKI) very
difficult.

In fact, the absence of sensitive AKI biomarkers has impaired progress in the

nephrology field and had a detrimental effect on the design and outcome of AKI clinical trials.
Recently, several proteins have shown potential in the early detection of acute and chronic
kidney injuries.

Areas covered: This review discusses the current status of kidney injury molecule-1 (KIM-1) as
a potential diagnostic tool in patients with various acute and chronic kidney diseases. The focus
is limited to human studies from January 2002 to July 2010. The review clarifies the clinical
conditions for which KIM-1 has the greatest potential utility for early detection of kidney injury.
It also demonstrates to the reader the barriers to the successful use of KIM-1 and other
biomarkers in clinical practice, and the future trials that will be needed to validate their use.

Expert opinion: Despite the early promise of biomarkers such as KIM-1 for the early detection
and prognosis of kidney disease, more studies are required to establish their utility in clinical
practice. Indeed, the published clinical studies of urine KIM-1 so far are small and insufficient
to support clinical studies of urine KIM-1 as an effective AKI diagnostic test in humans. It is
suggested, through the heterogeneity of AKI and existing published data, that more than one
biomarker may be necessary to obtain sufficient sensitivity and specificity for AKI screening.
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Article Highlight Box
•

KIM-1 is a urinary biomarker for acute tubular injury in pediatric and adult patients. Its
continuing evaluation in early detection and severity of AKI will require larger
prospective studies to establish a cutoff value that is predictive of AKI as well as its
temporal expression patterns.

•

In the kidney transplant population, tissue KIM-1 is sensitive for kidney injury but not
specific for acute rejection.

Urinary KIM-1 did not perform better than traditional

markers in predicting chronic allograft failure or delayed graft function.
•

Further studies to confirm the association between KIM-1 and subtypes of RCC may lead
to a non-invasive means of early detection of RCC.

•

Conflicting data regarding the association between KIM-1 and proteinuria leave the
clinical use of KIM-1 in the CKD population in question.

1] Introduction
1.1 Acute kidney injury
Acute kidney injury (AKI) is an important cause of morbidity and mortality in hospitalized
patients. One or more events of ischemic insult and nephrotoxic injury to the kidney are the
main cause of hospital acquired AKI. The incidence of hospital acquired AKI varies from 5% in
patients with normal renal function to 25% in intensive care unit (ICU) patients [1-3]. Mortality
rates of patients with postoperative AKI range from 50 to 70% among ICU patients who require
renal replacement therapy (RRT) [4, 5]. For the last 30 years, the mortality rate of patients with
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severe AKI requiring RRT in the ICU has not decreased significantly despite advances in
supportive care, including continuous RRT.

1.2 Limitation of current AKI criteria
A standard definition of AKI is lacking, with > 30 definitions used for diagnosis of AKI in
published studies, most based on serum creatinine (Scr) values. Two new definitions of AKI
have been developed recently: RIFLE (risk, injury, failure, loss, and end stage renal disease) and
AKIN (acute kidney injury network) criteria (Table 1) [6, 7]. However, timely detection of AKI
with current RIFLE and AKIN criteria remains challenging because these definitions are entirely
based on increases in Scr or decreases in urine output. Serum creatinine is insensitive for the
early detection of AKI because the change in Scr does not discriminate the time and type of renal
insult or the site and extent of glomerular or tubular injury [8].
The lack of reliable biomarkers for early detection of injury leads to delay in the
introduction of treatment until well into the course of the renal injury. Therefore, many potential
therapeutic agents showed little success in human studies [9-13]. There is no single or sequence
of clinical interventions that will significantly improve renal function after onset of acute tubular
injury or necrosis at the present time. Dialysis remains the only FDA-approved treatment option
for established AKI.

1.3 Limitation of assessment of progressive loss of renal function
Chronic kidney disease (CKD) is characterized by a progressive loss of kidney function. The
traditional methods of assessing kidney function decline are by serial measurement of Scr,
reciprocal slope of Scr, or 24 hour creatinine clearance [14]. Changes in these markers appear
relatively late in progressive CKD, at which point many interventions will be less effective than
had they been introduced much earlier in the course of the injury. Even though proteinuria has
4

been implicated as a good marker of progressive decline in kidney function [15], it may not
present in many types of renal injury such as hypertensive renal disease and tubulointerstrial
disease.

Long-term renal outcome is determined by the severity of tubulointerstitial

involvement. Sensitive tubular injury biomarkers may predict disease progression earlier and
lead to more timely treatments before the development of elevated Scr or proteinuria. Thus, it is
a logical step to evaluate whether sensitive AKI biomarkers can predict the progression of CKD
in longitudinal studies.

1.4 New biomarkers under evaluation
Recently, several proteins emerged in animal and human studies as sensitive and specific AKI
biomarkers capable of detecting injury early and grading its severity, including kidney injury
molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), interleukin 18 (IL-18),
and L-fatty acid binding protein (L-FABP) [16-18]. The authors focus this review on KIM-1,
which has shown promise in human studies not only in AKI, but also in CKD, kidney
transplantation, and renal cell carcinomas (RCCs).

2] Kidney Injury Molecule-1
2.1 KIM-1 kidney expression and function in human
Human KIM-1 is a type 1 transmembrane glycoprotein containing a novel 6-cysteine
immunoglobulin-like domain and a threonine/serine and proline-rich domain characteristic of
mucin-like O-glycosylated proteins (Figure 1) [19]. KIM-1 is also known as hepatitis A virus
cellular receptor 1 and T-cell immunoglobulin- and mucin-domain-containing molecule 1 [2022]. The KIM-1 family consists of eight members in mice, six in rats and three in humans [23,
5

24]. KIM-1 protein is not detectable in normal kidney tissue or urine but is expressed at high
levels in dedifferentiated proximal tubule epithelial cells in human and rodent kidneys after
ischemic or toxic injury, and in RCC [19, 25-28]. The soluble KIM-1 protein that appears in the
urine of humans is about 90kDa.
It is unclear whether expression of KIM-1 is related to the pathogenesis of the injury
itself or marker of attempted recovery and repair. Ichimura et al. [29] demonstrated that KIM-1
is a scavenger receptor on renal epithelial cells, which play a central role in removal of apoptotic
debris from tubular lumen. Furthermore, KIM-1 has been implicated in immune responses that
regulate the development of autoimmune and allergic diseases [30-33]. KIM- 1 may play an
important role in modulating the immunogenicity of RCC because RCC is an intrinsically
immunogenic tumor [34].
interstitial fibrosis [35].

In addition, KIM-1 has been associated in the development of
However, these associations are speculative and further studies are

necessary to determine the functional role of KIM-1 in various renal diseases.

2.2 Methods of quantitation and stability of urinary KIM-1 proteins
Several methods have been used for urinary KIM-1 measurement in published studies. In the
initial study, urinary KIM-1 protein was measured by direct sandwich enzyme-linked
immunosorbent assay (ELISA) using monoclonal antibody and confirmed by western blot
analysis [25]. Subsequent clinical studies have utilized customized direct sandwich ELISA or
microsphere-based Luminex xMAP technology using a commercially available polyclonal KIM1 antibody (R&D systems, Minneapolis, MN, USA) [36, 37]. Twenty to 30 µl urine samples are
needed for both platforms. The inter- and intra-assay coefficients of variation are reported to be
<10%. Recently, KIM-1 RenaSticks (Argutus Medical, Dublin, Ireland) were developed as a
rapid diagnostic assay for rat and human kidney injuries [38]. However, there is very limited
data for human urine samples. It appears to work well for high KIM-1 values.
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Urinary KIM-1 protein did not degrade significantly up to 24 h in 4°C and in room
temperature, and after prolonged storage at -80°C for 2 years with repeat freeze and thaw cycles
[36]. Addition of protease inhibitor was not necessary to prevent degradation of urinary KIM-1
protein.

This finding is critical to continuing validation studies of potential tandem AKI

biomarkers.

3] Clinical applications of KIM-1
The following section discusses in detail the potential role of KIM-1 as a biomarker in various
kidney diseases in humans.

3.1 Acute Kidney Injury
KIM-1 has been implicated as a urinary biomarker for acute tubular injury in both the hospital
in-patient setting (Table 2) and before cardiac surgery or catheterization (Table 3).

3.1.1 Cross-sectional study. In a small cross-sectional study, Han et al. [25] demonstrated that
the soluble form of cleaved KIM-1 could be detected in the urine of patients with established
AKI, and found elevated urinary KIM-1 levels within 12 h after an initial ischemic insult, before
the appearance of granular casts in the urine. Tissue expression of KIM-1 was also evaluated in
biopsy samples of six patients with pathologically confirmed ATN and showed extensive
expression of KIM-1 in the proximal tubules in all cases. Although promising, most of the urine
samples were collected late into the course of kidney injury, some at the time of peak Scr. Thus,
the relationship between severity of kidney injury and biomarker elevation could not be
evaluated.
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Vaidya et al. [37] investigated the diagnostic performance of nine urinary biomarkers in a
cross-sectional study. When compared to non-AKI patients (n=102), urinary KIM-1 showed
strong diagnostic performance in detecting established AKI (n=102) with the area under the
receiver operating characteristics curve (AUC-ROC) of 0.93. KIM-1 was also found to be a
significant predictor of mortality (P<0.001), but not a predictor of RRT or the composite of
mortality and RRT. Of note, no patients with underlying CKD were enrolled in the study, thus
excluding a large population of subjects who frequently develop AKI in clinical practice.
Urinary biomarkers were also measured at unknown and at variable times relative to AKI.
Overall, the above cross-sectional studies established that urinary KIM-1 could
differentiate patients with established AKI from patients without AKI.

However, a cross-

sectional study gives no indication of whether urinary KIM-1 is useful for early detection and
prognosis of AKI.

3.1.2 Prospective study. The following studies evaluated the temporal expression patterns of
urinary KIM-1 from onset of renal insult. The diagnostic utility of urinary KIM-1 was evaluated
for the early detection of postoperative AKI after pediatric cardiac surgery in a case control study
[39] using samples from the same cohort in the NGAL study previously described [40]. In that
study, urinary NGAL was measured and found to have an AUC-ROC of 0.99 and 1.00 at 2 and 4
h, respectively, following cardiopulmonary bypass (CPB). A subsequent study using all of the
AKI cases and under half of the non-AKI cases showed urinary IL-18 to have an AUC-ROC of
0.61 at 4 h, 0.75 at 12 h, and 0.73 at 24 h following CPB [41]. Urinary KIM-1 had an AUCROC of 0.57 at 2 h, 0.83 at 12 h, and 0.78 at 24 h. Comparisons among the three biomarkers
(NGAL from the original study and IL-18 and KIM-1 at later dates using frozen samples) should
be made with caution for several reasons. The cohorts were all children with a small sample
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size. CKD patients were excluded from the cohort. There were no patients who required
dialysis or died.
Han et al. [36] also conducted a prospective study in 90 adults undergoing cardiac
surgery at a single institution where AKI was defined as an increase in Scr of ≥0.3 mg/dl within
72 h after surgery. The AUCs to predict AKI (n=36) immediately and 3 h after operation were
0.68 and 0.65 for KIM-1; 0.61 and 0.63 for N-acetyl-β-glycosaminidase (NAG); and 0.59 and
0.65 for NGAL, respectively. Combining the three biomarkers enhanced the sensitivity of early
detection of post-operative AKI compared with individual biomarkers. The AUCs for the three
biomarkers combined were 0.75 and 0.78. However, direct comparison of Scr with urinary
biomarkers for the detection of AKI was not done. In addition, how to combine multiple
biomarkers for clinical use remains a challenge.
Liangos et al. [42] prospectively compared the performance characteristics of six urinary
biomarkers in 103 patients following CPB for the early detection of AKI. KIM-1, NAG, NGAL,
IL-18, cystatin C, and α-1 microglobulin were measured at 2 h postoperatively. AKI was
defined as an increase in Scr by ≥50% in the first 72 h after termination of CPB. Among the
biomarkers, KIM-1 had the highest predictive performance (AUC-ROC 0.78), and remained
independently associated with AKI after adjusting for a preoperative AKI prediction score. This
study was limited because there were a small number of patients and a single timed urine
collection after operation. Only one patient who developed AKI required dialysis (n=13).
In a small prospective study, Malyszko et al. [43] evaluated the utility of urinary
biomarkers for detection of contrast-induced nephropathy (CIN) in 140 patients without CKD
after cardiac catheterization.

Seventeen patients developed CIN, which was defined as an

increase in SCr ≥ 25% from baseline within 48 h of cardiac catheterization. Urinary KIM-1 level
was increased at 24 and 48 h post-catheterization for the CIN group, but without statistical
9

significance. Serum and urinary NGAL levels increased significantly within the first 4 h of
catheterization among patients with CIN.

However, the study was very limited because there

was no information on severity and outcome of CIN. In addition, there was no direct comparison
of Scr with urinary biomarkers for the detection of CIN.
Biomarkers have been increasingly used in the critical care setting for diagnosis and risk
stratification.

High urinary KIM-1 expression was also associated with adverse clinical

outcomes in patients with established AKI. In a cohort of 201 patients with established AKI,
Liangos et al. [44] demonstrated that urinary KIM-1 and NAG were significantly associated with
the clinical composite endpoints of death or RRT with an AUC-ROC of 0.78. However, when
adjusted for disease severity (by APACHE II Score or MOF Score), or for comorbidities
(including cirrhosis, sepsis, oliguria, and mechanical ventilation), urinary KIM-1 level lost its
statistical significance.
Studies available at present are all insufficiently powered to establish a cutoff value that
is predictive of AKI. All in all, larger prospective studies are necessary to validate the temporal
expression pattern of urinary KIM-1 for early detection of AKI, and to establish how the
temporal course relates to the onset, severity, and outcome of AKI.

3.2 Renal allograft
The early promise of KIM-1 as an AKI biomarker led to its study in other settings, including the
kidney transplant population (Table 4). KIM-1 has been evaluated as a biomarker for delayed
graft dysfunction, acute rejection and chronic damage through assessment of urinary excretion
and kidney biopsy tissue expression.
KIM-1 expression has been implicated as a specific histological biomarker for diagnosing
tubular injury on renal transplant biopsies. Zhang et al. [45] described tissue KIM-1 expression
in 65 kidney allograft biopsies grouped by histological diagnosis (normal protocol biopsy, acute
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tubular injury without cellular rejection, and acute cellular rejection). KIM-1 was expressed in
100% of cases with acute tubular injury without rejection and in 92% of cases of acute cellular
rejection. There was, however, no urine KIM-1 data available for correlation with tissue KIM-1
expression.

Meanwhile, Nogare et al. [46] also reviewed 59 kidney transplant biopsies,

classified by Banff 1997 criteria into five groups: ATN; ATN with acute rejection episode
(ATN/ARE); acute rejection episode without ATN (ARE); chronic calcineurin inhibitor toxicity
(CNI); and interstitial fibrosis and tubular atrophy (IFTA). Tissue KIM-1 mRNA expression
levels were increased in the CNI and IFTA groups but decreased in the other three groups. This
result conflicts with earlier findings that KIM-1 is strongly associated with ATN.
Kidneys from brain death donors are susceptible to injury prior to kidney transplantation
because brain death negatively affects hemodynamic stability and hormone regulation in the
donor [47, 48]. Unlike previous studies in the allograft population, Nijboer et al. [49] evaluated
KIM-1 before and after organ procurement. There was a 2.5-fold increase in allograft tissue
KIM-1 gene expression among the donation after brain death (DBD) group (n=20) compared
with living related group (n=20). Whereas there was no difference in urinary KIM-1 between the
two groups before organ procurement, there was a twofold increase in urinary KIM-1 during
organ recovery in the DBD group. Baseline urinary KIM-1 levels before procurement have been
implicated as an independent predictor of Scr at 14 days and 1 year after transplantation. This
study is limited by its small sample size and lack of clinical events noted during the procurement
and transplant periods.
van Timmeren et al. [50] investigated the utility of urinary KIM-1 in predicting chronic
kidney allograft loss in 145 kidney transplant recipients. Patients were divided into tertiles based
on urinary KIM-1 levels, and higher tertile was associated with increased occurrence of graft
loss, resulting in return to dialysis or re-transplantation. In terms of predictive performance for
allograft loss within 5 years, AUC-ROC for KIM-1 level was 0.71, suboptimal when compared
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with proteinuria (0.82) and creatinine clearance (0.89).

There was no clinical information about

etiologies of chronic kidney allograft dysfunction.
Hall et al. [51] evaluated the performance of urinary AKI biomarkers in predicting
delayed graft function and renal recovery among deceased donor kidney transplants. This multicenter prospective study is the largest so far (n=91) to follow prospectively recipients
immediately after transplant with serial urinary IL-18, NGAL, and KIM-1 levels. Urinary IL-18
and NGAL showed statistically significant difference between delayed graft function, slow graft
function, and immediate graft function groups. Also, urinary IL-18 and NGAL were positive
predictors for need for dialysis in 1 week and for graft recovery over 3 months after
transplantations. Urinary KIM-1 performed poorly in this immediate post-transplantation cohort.
Schroppel et al. [52] also investigated the post-transplant population by assessing both preperfusion tissue KIM-1 (n=115) and urinary KIM-1 (n=38) levels as predictors of delayed graft
function. There was no correlation between urinary KIM-1 and tubular KIM-1 expressions in
kidney allografts. Though pre-perfusion tissue KIM-1 expression inversely correlated with renal
function at the time of organ procurement, there was no correlation between KIM-1 staining
intensity and occurrence of delayed graft function.
As in AKI, the available studies assessing KIM-1 in the transplant population show that it
is a sensitive tissue biomarker for injury. However, urinary KIM-1 did not perform better than
traditional markers in predicting chronic allograft failure. Urinary KIM-1 also did not perform
well in the immediate post-transplantation cohort as a biomarker for predicting delayed graft
function and need for dialysis within the first week of kidney transplantation.

3.3 Renal cell carcinoma
As KIM-1 is strongly upregulated in proximal tubular cells in states of cell dedifferentiation, two
studies evaluated the possible relationship of KIM-1 with RCC (Table 5). Han et al. [27]
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investigated the association of tissue KIM-1 expression with RCC in 74 patients. Ninety-one per
cent of clear cell RCC (n=56) stained positively for tissue KIM-1. Urinary KIM-1 levels were
also significantly higher among RCC patients (n=42) compared with those with prostate cancer
(n=10) or normal controls (n=30).

Urinary KIM-1 levels decreased markedly or disappeared

post-nephrectomy. The findings were limited by the retrospective nature of the study and small
sample size.
A larger evaluation of tissue KIM-1 expression was published by Lin et al. [28] with 480
biopsies of various neoplasms analyzed. One hundred and seventy-nine biopsy samples of RCC
were analyzed by tissue microarray, and 301 other samples (80 kidney and 221 non-kidney
tumors) were evaluated by immunohistochemistry. Seventy-four per cent of clear cell, 93% of
papillary, and 78% metastatic RCC were differentiated from chromophobe RCC and
oncocytomas by markedly different degrees of KIM-1 expression. Of note, tissue KIM-1 was
found to be highly positive in certain non-renal cancers, including 93.8% of clear cell carcinoma
of the ovary and 33% of clear cell carcinoma of the uterus. Though this retrospective analysis
provided new possible utilities of KIM-1 in detecting non-renal cancers, further studies are
needed to clarify the mechanisms and clinical importance of this finding.
Study in a larger number of patients is necessary to establish the sensitivity and
specificity of KIM-1 in RCC, as well as the temporal relationship between diagnosis of RCC and
rise in urinary KIM-1 levels. If further studies confirm association of KIM-1 with subtypes of
RCCs, this may provide a non-invasive means of early detection and a potential screening tool in
high-risk patients.

3.4 Chronic kidney disease
KIM-1 has also been evaluated as a predictor of disease progression in CKD (Table 5). van
Timmeren et al. [35] studied the KIM-1 expression in human kidney biopsies (n=102) and its
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correlation with urinary KIM-1 (n=53) at the time of biopsy in patients with various types of
CKD.

Tissue and urinary KIM-1 expression correlated positively with interstitial damage,

inflammation, and Scr, but did not correlate with proteinuria. To explain this, the authors
suggest that not all proteinuria is accompanied by tubulointerstitial damage and progressive
decline in renal function, using minimal change disease (MCD) as an example. Waanders et al.
[53] also studied proteinuria and KIM-1 by analyzing effect of anti-proteinuric regimens of diet
and RAAS inhibition on KIM-1 and NAG. In non-diabetic Stage III CKD, decreased urinary
KIM-1 correlated with decreased proteinuria in each interventional group studied, but not with
blood pressure or creatinine clearance. The study suggests that improvement of proteinuria will
result in decreased tubulointerstitial damage as reflected by urinary KIM-1. Major limitations of
this study include its small sample size, exclusion of diabetics, short duration (maximum six
weeks for any given intervention), and single urinary sample obtained after intervention.
Prospective studies that extend beyond six weeks are necessary in assessment of CKD and
response to therapy.
Conflicting results exist regarding the role of KIM-1 in evaluation of CKD, particularly
its relationship with proteinuria. The question remains whether urinary KIM-1, used in tandem
with urine protein-to-creatinine ratio, can enhance detection of kidney disease progression and
future need for dialysis, and whether such information can lead to more aggressive treatment and
improved outcome.

4] Conclusion
KIM-1 is expressed exclusively in injured proximal tubules and shed in the urine during tubular
injury, making it readily detectable in the urine. The variety of human studies evaluating tissue
and urinary KIM-1 across various kidney diseases has provided insight into its utility. KIM-1
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expression is not only highly elevated in acute tubular injury, but also detectable in various
etiologies of AKI, CKD, the kidney transplant population, and RCC. New questions arose from
these studies, namely the mechanism of KIM-1 expression in non-renal disorders, from
hospitalization without history or biochemical marker of kidney disease to non-renal clear cell
carcinomas.
Available studies have also highlighted several limitations of KIM-1 in the detection and
prediction of kidney injury and disease, which preclude the mainstream acceptance of KIM-1 in
the clinical setting. Most of the human studies come from single centers and from homogeneous
patient populations. Urinary KIM-1 has been tested only in small studies and limited clinical
situations. Most studies assessing AKI exclude CKD patients.

Existing studies have been

insufficiently powered to establish a cutoff value that is predictive of AKI. In addition, there is
at present very limited data available regarding temporal expression patterns of urinary KIM-1 in
the various clinical settings of AKI from onset of renal insult or utility for differentiating causes
of AKI. Furthermore, there is no report on detecting soluble KIM-1 in serum samples of AKI
patients. Studies investigating CKD are few, and the results are conflicting with regards to
association of KIM-1 with proteinuria. Tissue KIM-1 is a sensitive biomarker for kidney injury
in the kidney transplant population, but existing studies have not shown ability to discriminate
between types of injury or to predict graft failure. So far, clinical utility of KIM-1 in human
studies has been more promising in AKI and RCC populations than in kidney transplant or CKD
populations.

5] Expert Opinion
The particular area of biomarker research that remains most interesting is in AKI population
because they can have their greatest impact on clinical care. The goal of early detection of AKI
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is the introduction of therapy early enough in the disease process to reduce the high mortality
rate associated with AKI.
The search for new AKI biomarkers has been evolving rapidly with advancement in
modern technologies. Recently, several protein biomarkers, including KIM-1, NGAL, IL-18,
cystatin C, and L-FABP, emerged through the application of functional genomics and proteomics
to human and animal models of AKI. However, several requirements must be met for their use
in daily clinical practice. The AKI biomarkers must: i) allow for early detection of kidney
injury; ii) identify severity of AKI; iii) provide a rationale for risk stratification for clinical
studies including the identification of patients at risk for AKI; iv) guide timing of therapy; v)
reflect improvement and worsening of the kidney injury; and vi) be amenable to quick and
reliable measurement at the bedside or in the clinical laboratory. Unfortunately, none of these
biomarkers has demonstrated a clear benefit in various types of AKI. The published clinical
studies of urine KIM-1 are small so far, and there is no clear evidence whether urinary KIM-1 is
an effective AKI diagnostic test in humans.
The heterogeneity of AKI and existing published data suggest that more than one
biomarker may be necessary to obtain sufficient sensitivity and specificity for AKI screening.
There is emerging evidence that combining multiple biomarkers may allow early detection of
AKI [36, 39], but how to combine multiple biomarkers for clinical use remains a challenge. As
such, there is at present no standard way to combine the multiple biomarkers for clinical use.
The ultimate goal of a more sensitive biomarker or panel of biomarkers is improved early
detection and monitoring of AKI and other kidney disease, which will lead to improved
outcomes through earlier therapeutic intervention and the re-evaluation of other pharmacologic
agents that have shown promise in experimental models.
KIM-1 or other biomarker research is past cross-sectional measurement unrelated to a
clinically or biochemically defined end point. The inherent benefit of AKI biomarkers is for
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making an early diagnosis of AKI that correlates with future declines in function as detected by
changes in Scr, not when Scr is already grossly elevated. Future studies must continue to move
from assessment of KIM-1 to more directed measurement in close temporal relationship to
injury. Larger prospective multi-center studies are necessary to validate the temporal expression
pattern of urinary KIM-1 for early detection of AKI, and to elucidate how this temporal course
relates to the onset, severity, and outcome of AKI. Recently, the NIH launched the Translational
Research Investigating Biomarkers Endpoints in AKI study, which is a multi-center prospective
observational study to validate biomarkers for early diagnosis and prognosis of AKI after cardiac
surgery among adult and pediatric patients. More such prospective studies that are sufficiently
powered to establish a cutoff value that is predictive of AKI, especially with severe injury, are
needed. Then a new standard definition of AKI not based on a change in Scr can be proposed.
Multiple challenges have prevented the clinical use of new biomarkers in early detection of AKI.
The use of an imperfect marker in the authors’ definition of AKI, Scr, has certainly contributed
to this difficulty. A new definition of AKI should be based on multiple biomarkers, used in the
setting of careful clinical assessment and other clinical and laboratory parameters, to detect
initial renal injury within minutes to hours.
Once a more sensitive biomarker or panel of biomarkers for AKI is validated for clinical
use, the next challenging tasks are the development of a rapid assay and the selection of a
suitable patient group for pharmacologic treatment. Current quantification methods include
ELISA, Luminex, and nephelometry. Rapid assays must improve upon current technologies and
provide a quick and reliable measurement at the bedside or clinical laboratory for the detection
of AKI. Then multiple therapeutic possibilities that showed promise in animal studies, but failed
in human studies, can be revisited in clinical trials. Furthermore, it is critical to know the timing
of the kidney insult because previous animal studies and failed attempts of human intervention
clinical trials demonstrate that introduction of treatment should precede the rise of Scr and be
17

very early after the insult.

This may limit the utility of AKI biomarkers and potential

pharmacologic treatments to patients with hospital acquired AKI, including post-operative or
contrast-dye induced AKI.
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Figure 1. Structure of human KIM-1. The protein is a type 1 transmembrane glycoprotein with
most of the protein made of an extracellular domain that consists of a signal peptide,
immunoglobulin-like domain and a mucin domain.

The protein is cleaved by a

metalloproteinase and the ectodomain (90 kDa) appears in the urine of humans with acute kidney
injury and renal cell carcinoma.
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Table 1. RIFLE and AKIN Staging Criteria for AKI
Stage

Creatinine Criteria

Urine Output Criteria

1

Increase in Scr of ≥ 0.3 mg/dl or
increase in Scr of 1.5 to 2.0 fold from baseline

<0.5 ml/kg per h for 6 h

2

Increase in Scr of 2.0 to 3.0 fold from baseline

<0.5 ml/kg per h for 12 h

3

Increase Scr to > 3.0 fold from baseline or
Scr > 4 mg/dl with an acute rise of ≥ 0.5 mg/dl

<0.3 ml/kg per h x 24 h or
anuria for 12 h

Stages removed from RIFLE criteria in AKIN stages
Loss
ESRD

Persistent acute renal failure=complete loss of kidney function > 4 weeks
End-stage kidney disease (> 3 months)

AKIN, acute kidney injury network; AKI, acute kidney injury; RIFLE, risk, injury, failure, loss, ESRD;
Scr, serum creatinine
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able 2. Clinical study for KIM-1 as a Biomarker for Acute Kidney Injury in Hospitalized Patients

inical
udy
an et
[25]

Year

angos
al.
4]

2007

aidya
al.
7]

2008

2002

Study
population
Hospitalized
patients with
AKI vs nonhospitalized
controls
(n=40)
Hospitalized
patients with
AKI (n=201)
Hospitalized
patients with
AKI vs nonhospitalized
controls
(n=204)

Type of
study
Crosssectional

Comparison
biomarkers
alkaline
phosphatase,
γ-glutamyltransferase,
total protein

Measurement

Method of
detection
Sandwich
ELISA

Major findings

Limitations

High KIM-1 expression
in acute tubular injury.
KIM-1 is elevated in
AKI compared to nonAKI group

Small sample size. Most uri
samples were drawn late into
course of kidney injury.

Prospective

NAG

Urine KIM-1

Luminex

Timing of measurement
dependent on time of renal
consult

Urine KIM-1

Sandwich
ELISA

KIM-1 and NAG
associated with the
clinical composite of
death and need for RRT.
KIM-1 has a good
discriminatory
characteristic of AKI
biomarker. Not a
predictor of RRT or the
composite of mortality
and RRT.

Crosssectional

NGAL, IL18, NAG,
HGF,
cystatin C,
VEGF, IP10, total
protein

Tissue KIM-1
&
Urine KIM-1

Small number of hospitalized
patients as a control group.
Elevated KIM-1 levels in
hospitalized patients without
AKI. No inclusion of CKD
patients.

AKI, acute kidney injury; CKD, chronic kidney disease; ELISA, enzyme-linked immunoabsorbent assay;
HGF, hepatocyte growth factor; IL-18, interleukin 18; IP-10, interferon-inducible protein-10; KIM-1,
kidney injury molecule-1; NAG, N-acetyl-β-glucosaminidase; NGAL, neutrophil gelatinase associated
lipocalin; RRT, renal replacement therapy; VEGF, vascular endothelial growth factor.
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Table 3. Clinical Study for KIM-1 as a Biomarker for Post-operative Acute Kidney Injury and Contrast-Induced Nephropath
Clinical
Study
Type of
Comparison
Method of
study
Year population
study
biomarkers
Measurement detection
Major findings
Han et al.
2008 AKI vs nonCrossNAG, MMP-9 Urine KIM-1
Sandwich
KIM-1 can allow early
[39]
AKI (n=74).
sectional
ELISA
diagnosis of post-operative
Children with
and CaseAKI before a rise in Scr
cardiac surgery
control
(n=40)
Liangos
et al. [42]

2009

Adults with
cardiac surgery
(n=103)

Prospective

Han et al.
[36]

2009

Adults with
cardiac surgery
(n=90)

Prospective

Malyszko
et al. [43]

2009

Adults with
cardiac
catheterization
(n=140)

Prospective

NAG, NGAL,
Cystatin C,
IL-18, Alpha-1
microglobulin
NAG, NGAL

NGAL, IL-18,
Cystatin C,
L-FABP

Urine KIM-1

Sandwich
ELISA

KIM-1has the best
predictive value for
detection of AKI.

Urine KIM-1

Sandwich
ELISA

Urine KIM-1

Commercial
kit

A panel of AKI biomarkers
may improve the early
detection of postoperative
AKI
KIM-1 tends to be higher a
24 and 48 hours postcatheterization in CIN
group, but it is not
statistically significant

AKI, acute kidney injury; CIN, contrast-induced nephropathy; CKD, chronic kidney disease; ELISA,
enzyme-linked immunoabsorbent assay; IL-18, interleukin 18; KIM-1, kidney injury molecule-1; L-FABP,
L-fatty acid binding protein; MMP-9, matrix metalloproteinase 9; NAG, N-acetyl-β-glucosaminidase;
NGAL, neutrophil gelatinase associated lipocalin; Scr, serum creatinine.
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1 as a biomarker in transplant population

Type of
study
Prospective

Other
Biomarkers
No

Measurement

Retrospective

No

Tissue KIM-1

IHC

Prospective

No

Tissue KIM-1
mRNA &
Urine KIM-1

Real-time
PCR
Sandwich
ELISA

Significant increase KIM-1 in
DBD kidneys and urine after
procurement.

Retrospective

No

Tissue KIM-1
mRNA

Real-time
PCR

KIM-1 mRNA levels are
increased in the CNI and IFTA
categories, but not in ATN or

Urine KIM-1
(24-hour)

Detection
Method
Luminex

Major findings

Limitations

Highest tertile of KIM-1
independent predictor of graft
loss when adjusted for age,
creatinine clearance and
proteinuria
KIM-1 expressed in ATI and
ACR; KIM-1 in 28% of normal
biopsy; KIM-1 correlated with
renal dysfunction

Single center. Single 24-hour
urine sample. Wide variation
of time of inclusion allows for
healthy survivor bias. No
histological correlation.
Among normal protocol
biopsies, no clinically
significant difference in renal
function regardless of KIM-1
staining.
Single center study. Small
sample size. Precise timing of
when samples taken not
specified.
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Non-diverse population.
Single center. Indication or
timing of biopsy from injury

ARE.

Prospective

NGAL,
IL-18

Urine KIM-1

Sandwich
ELISA

KIM-1 is not correlated to graft
function. IL-18 and NGAL
statistically significant difference
between three groups.

Prospective

No

Tissue KIM-1
mRNA and
protein &
Urine KIM-1

IHC PCR
Luminex

No significant correlation
between KIM-1 and presence or
absence of DGF. KIM-1 is not
correlated to graft function.

not specified. No clinical
correlation.
Small sample size.

Small sample size.

ACR, acute cellular rejection, ARE, acute rejection episode; ATI, acute tubular injury; ATN, acute tubular
necrosis; CNI, calcineurin inhibitor toxicity; CRT, cadaveric renal transplant; DBD, donation after brain
death; DGF, delayed graft function; IFTA, interstitial fibrosis and tubular atrophy; IGF, immediate graft
function; IHC, immunohistochemistry; LRT, living related transplant; PCR, polymerase chain reaction;
SGF, slow graft function
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Table 5. Clinical Study of KIM-1 as a Biomarker in RCC and CKD
Clinical
Study
Han et al.
[27]

Year

Study Population

Type of Study

Other
Biomarkers
RCC-Ma

Measurement
Tissue and
Urine KIM-1

Detection
Method
IHC,
ELISA

2005

Renal tumor
(n=82) vs. Nonrenal tumor
(n=484)

Retrospective
&
Prospective

Lin et al.
[28]

2007

Renal tumor
(n=259) vs. Nonrenal tumor
(n=221)

Retrospective

No

Tissue KIM-1

IHC

van
Timmeren
et al. [35]

2007

CKD tissue
(n=102) and
urine (n=57)

Retrospective

No

Tissue and
Urine KIM-1

IHC,
ELISA

Waanders
et al. [53]

2009

Stable CKD Stage
III, proteinuric,
non-diabetic
(n=34)

Prospective
post-hoc
analysis

NAG,
Total protein

Urine KIM-1
(24 hour)

Luminex

Major Findings

Tissue KIM-1 in clear cell
RCC vs non-RCC. Urine
KIM-1 in RCC. Marked
decrease/disappearance K
in RCC post-nephrectomy
Increased KIM-1 in clear
papillary cell, and metasta
RCC. KIM-1 expression
clear cell type non-renal
cancers.
Urine KIM-1 correlated w
tissue KIM-1, negative
correlation with renal
function; no correlation w
proteinuria.

Decrease in KIM-1 in all
treatment groups. Correla
with decreased proteinuria
not renal function.

CKD, chronic kidney disease; ELISA, enzyme-linked immunoabsorbent assay; KIM-1, kidney injury
molecule-1; NAG, N-acetyl-β-glucosaminidase; RCC, renal cell carcinoma; RCC-ma, RCC marker
(monoclonal antibody to a proximal tubule renal antigen)
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